Comparative drug tests make pharma see red. But market pressure to prove a drug's real-world value is likely to force even the most stubborn firm into the ring. Why be bull-headed? Adaptive trials can cut cost, time, and risk in half.
FDA's cautious approach to allowing drug manufacturers to communicate the economic value of drugs is contributing to an already poorly informed healthcare industry, and may be curtailing access to useful drugs.